NASDAQ:VCNX Vaccinex (VCNX) Stock Price, News & Analysis $1.00 0.00 (0.00%) As of 09/23/2026 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFDA EventsInsider TradesNews and TrendsSEC Filings About Vaccinex Stock (NASDAQ:VCNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vaccinex alerts:Sign Up Key Stats Today's Range$1.00▼$1.0150-Day Range$0.72▼$1.2552-Week Range$0.31▼$1.50Volume453 shsAverage Volume3,115 shsMarket Capitalization$2.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vaccinex, Inc. (NASDAQ:VCNX) is a clinical-stage biotechnology company developing antibody-based therapies for neurodegenerative diseases and cancer. The company uses its proprietary ActivMAb antibody-discovery platform to identify and develop monoclonal antibodies directed at challenging therapeutic targets. Vaccinex’s lead product candidate is pepinemab, an antibody designed to inhibit semaphorin 4D (SEMA4D), a protein involved in immune regulation, inflammation, and tissue damage. The company has evaluated pepinemab in clinical studies involving conditions including Huntington’s disease, Alzheimer’s disease, multiple sclerosis, and certain cancers, with development focused on potential treatments for neurological and immuno-oncology indications. Vaccinex is headquartered in Rochester, New York, and its programs are developed through clinical research collaborations and trials conducted in the United States and other locations. Maurice Zauderer, Ph.D., is the company’s co-founder, president, and chief executive officer.AI Generated. May Contain Errors. Read More Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VCNX Stock News HeadlinesVaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026July 8, 2026 | globenewswire.comVaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025April 29, 2026 | quiverquant.comQA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)Vaccinex Reports 2025 Annual Financial ResultsApril 29, 2026 | globenewswire.comVaccinex Inc.April 10, 2026 | barrons.comVaccinex announces $60M revenue sharing agreement with PDVDecember 23, 2025 | msn.comVaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s DiseaseDecember 23, 2025 | markets.businessinsider.comVaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s TreatmentDecember 23, 2025 | quiverquant.comQSee More Headlines VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed this year? Vaccinex's stock was trading at $1.0755 on January 1st, 2026. Since then, VCNX shares have decreased by 7.0% and is now trading at $1.00. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) released its earnings results on Monday, November, 8th. The company reported ($35.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($60.90) by $25.20. The firm had revenue of $0.05 million for the quarter. When did Vaccinex's stock split? Vaccinex's stock reverse split on the morning of Tuesday, February 20th 2024.The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Vaccinex IPO? Vaccinex (VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Pfizer (PFE), VBI Vaccines (VBIV), OPKO Health (OPK), Plug Power (PLUG), NIO (NIO) and SNDL (SNDL). Company Calendar Last Earnings11/08/2021Today9/24/2026Next Earnings (Estimated)11/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VCNX CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees40Year Founded2001Profitability EPS (Trailing Twelve Months)($48.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.25 million Net MarginsN/A Pretax Margin-4,787.89% Return on EquityN/A Return on Assets-383.58% Debt Debt-to-Equity RatioN/A Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$388 thousand Price / Sales6.70 Cash FlowN/A Price / Cash FlowN/A Book Value($2.59) per share Price / Book-0.39Miscellaneous Outstanding Shares2,600,000Free Float1,261,000Market Cap$2.60 million OptionableNo Data Beta1.10 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:VCNX) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
